Sara Gargiulo

Dr. Sara Gargiulo

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in ILAR Journal
Verified
Journal Article
Open access
PDF file
Sara GargiuloSara Gargiulo
Sara Gargiulo
AGAdelaide Greco
Adelaide Greco
MGMatteo Gramanzini
Matteo Gramanzini
SESilvia Esposito
Silvia Esposito
AAAndrea Affuso
Andrea Affuso
GVGIANCARLO VESCE
GIANCARLO VESCE
Animal experiments are necessary for a better understanding of diseases and for developing new therapeutic strategies. The mouse (Mus musculus) is currently the most popular laboratory animal in biomedical research. Experimental procedures on animals often require anesthesia and/or analgesia to obtain adequate immobilization and to reduce stress or pain. Mice anesthesia is challenging for several reasons including the animals' size, metabolic rate, and the high risk of hypothermia and hypoglycemia. Moreover, anesthetic agents influence physiological parameters, further interfering with experimental results. Small animal imaging procedures are increasingly used in biomedical research both because the animals allow in vivo monitoring and because they are readily available for longitudinal and noninvasive studies as well as investigations into the evolution of diseases and the effects of new therapies. Anesthesia must adapt to the imaging technique, the procedure length, and the aim of the study. The purpose of this article is to review the existing literature on anesthetic protocols adopted in mice for molecular imaging studies and to report our experience.

24 March 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LGLivia Garzia
Livia Garzia
Immacolata AndolfoImmacolata Andolfo
Immacolata Andolfo
ECEmilio Cusanelli
Emilio Cusanelli
NMNatascia Marino
Natascia Marino
GPGiuseppe Petrosino
Giuseppe Petrosino
FVFrancesca Valdora
Francesca Valdora
Through negative regulation of gene expression, microRNAs (miRNAs) can function in cancers as oncosuppressors, and they can show altered expression in various tumor types. Here we have investigated medulloblastoma tumors (MBs), which arise from an early impairment of developmental processes in the cerebellum, where Notch signaling is involved in many cell-fate-determining stages. MBs occur bimodally, with the peak incidence seen between 3–4 years and 8–9 years of age, although it can also occur in adults. Notch regulates a subset of the MB cells that have stem-cell-like properties and can promote tumor growth. On the basis of this evidence, we hypothesized that miRNAs targeting the Notch pathway can regulated these phenomena, and can be used in anti-cancer therapies. In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells. MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells. In our analysis of 61 patients with MB, the expression of miR-199b-5p in the non-metastatic cases was significantly higher than in the metastatic cases (P = 0.001). Correlation with survival for these patients with high levels of miR-199b expression showed a positive trend to better overall survival than for the low-expressing patients. These data showing the down-regulation of miR-199b-5p in metastatic MBs suggest a potential silencing mechanism through epigenetic or genetic alterations. Upon induction of de-methylation using 5-aza-deoxycytidine, lower miR-199b-5p expression was seen in a panel of MB cell lines, supported an epigenetic mechanism of regulation. Furthermore, two cell lines (Med8a and UW228) showed significant up-regulation of miR-199b-5p upon treatment. Infection with MB cells in an induced xenograft model in the mouse cerebellum and the use of an adenovirus carrying miR-199b-5p indicate a clinical benefit through this negative influence of miR-199b-5p on tumor growth and on the subset of MB stem-cell-like cells, providing further proof of concept. Despite advances in our understanding of the pathogenesis of MB, one-third of these patients remain incurable and current treatments can significantly damage long-term survivors. Here we show that miR-199b-5p expression correlates with metastasis spread, identifying a new molecular marker for a poor-risk class in patients with MB. We further show that in a xenograft model, MB tumor burden can be reduced, indicating the use of miR199b-5p as an adjuvant therapy after surgery, in combination with radiation and chemotherapy, for the improvement of anti-cancer MB therapies and patient quality of life. To date, this is the first report that expression of a miRNA can deplete the tumor stem cells, indicating an interesting therapeutic approach for the targeting of these cells in brain tumors.

10 July 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Sara GargiuloSara Gargiulo
Sara Gargiulo
MGMatteo Gramanzini
Matteo Gramanzini
RMRosario Megna
Rosario Megna
AGAdelaide Greco
Adelaide Greco
SASandra Albanese
Sandra Albanese
ABArturo Brunetti
Arturo Brunetti
The normal growth pattern of female C57BL/6J mice, from 5 to 30 weeks of age, has been investigated in a longitudinal study. Weight, body surface area (BS), and body mass index (BMI) were evaluated in forty mice. Lean mass and fat mass, bone mineral content (BMC), and bone mineral density (BMD) were monitored by dual energy X-ray absorptiometry (DEXA). Weight and BS increased linearly (16.15±0.64–27.64±1.42 g;51.13±0.74–79.57±2.15 cm2,P<0.01), more markedly from 5 to 9 weeks of age(P<0.001). BMD showed a peak at 17 weeks (0.0548±0.0011 g/cm2*m,P<0.01). Lean mass showed an evident gain at 9 (15.8±0.8 g,P<0.001) and 25 weeks (20.5±0.3 g,P<0.01), like fat mass from 13 to 17 weeks (2.0±0.4–3.6±0.7 g,P<0.01). BMI and lean mass index (LMI) reached the highest value at 21 weeks (3.57±0.02–0.284±0.010 g/cm2, resp.), like fat mass index (FMI) at 17 weeks (0.057±0.009 g/cm2) (P<0.01). BMI, weight, and BS showed a moderate positive correlation (0.45–0.85) with lean mass from 5 to 21 weeks. Mixed linear models provided a good prediction for lean mass, fat mass, and BMD. This study may represent a baseline reference for a future comparison of wild-type C57BL/6J mice with models of altered growth.

30 April 2019 in Contrast Media & Molecular Imaging
Verified
Journal Article
Open access
PDF file
Sara GargiuloSara Gargiulo
Sara Gargiulo
SASandra Albanese
Sandra Albanese
MMMarcello Mancini
Marcello Mancini
The optical imaging plays an increasing role in preclinical studies, particularly in cancer biology. The combined ultrasound and optical imaging, named photoacoustic imaging (PAI), is an emerging hybrid technique for real-time molecular imaging in preclinical research and recently expanding into clinical setting. PAI can be performed using endogenous contrast, particularly from oxygenated and deoxygenated hemoglobin and melanin, or exogenous contrast agents, sometimes targeted for specific biomarkers, providing comprehensive morphofunctional and molecular information on tumor microenvironment. Overall, PAI has revealed notable opportunities to improve knowledge on tumor pathophysiology and on the biological mechanisms underlying therapy. The aim of this review is to introduce the principles of PAI and to provide a brief overview of current PAI applications in preclinical research, highlighting also on recent advances in clinical translation for cancer diagnosis, staging, and therapy.

1 March 2015 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
CVCaterina Vicidomini
Caterina Vicidomini
MPMariarosaria Panico
Mariarosaria Panico
AGAdelaide Greco
Adelaide Greco
Sara GargiuloSara Gargiulo
Sara Gargiulo
ACAnna Rita Daniela Coda
Anna Rita Daniela Coda
SPSabina Pappatà
Sabina Pappatà

1 March 2012 in ILAR Journal
Verified
Journal Article
Open access
PDF file
Sara GargiuloSara Gargiulo
Sara Gargiulo
AGAdelaide Greco
Adelaide Greco
MGMatteo Gramanzini
Matteo Gramanzini
SESilvia Esposito
Silvia Esposito
AAAndrea Affuso
Andrea Affuso
GVGiancarlo Vesce
Giancarlo Vesce
Animal experiments are necessary for a better understanding of diseases and for developing new therapeutic strategies. The mouse (Mus musculus) is currently the most popular laboratory animal in biomedical research. Mice imaging procedures are increasingly used in preclinical research because they allow in vivo monitoring and they are readily available for longitudinal and noninvasive studies as well as investigations into the evolution of diseases and the effects of new therapies. New imaging techniques and sophisticated laboratory animal imaging tools are currently producing a large body of evidence about the possible interference of anesthesia with different imaging methods that have the potential to compromise the results of in vivo studies. The purpose of this article is to review the existing literature on molecular imaging studies in mice, to describe the effects of different anesthetic protocols on their outcome, and to report our own experience with such studies.